ESTRO 2024 - Abstract Book

S5804

RTT - Education, training, advanced practice and role developments

ESTRO 2024

1. The Royal College of Radiologists.The Future of Molecular Radiotherapy Services in the UK. London: The Royal College of Radiologists; 2021. Available at: https://www.rcr214-review-molecular-radiotherapy-services-uk.pdf. [Accessed 12 October 2023]. 2.The Royal College of Radiologists. Good practice guide for paediatric radiotherapy, 2nd ed. London: The Royal College of Radiologists; 2018. Available at: Good practice guide for paediatric radiotherapy, second edition (rcr.ac.uk).[Accessed 12 October 2023].

1853

Digital Poster

RTT-led follow-up using patient-reported outcome measures following prostate HDR-brachytherapy

Lauren A Oliver 1 , Sarah Stead 2 , Rebecca Hunter 1,3 , Isabel Syndikus 2 , Chinnamani Eswar 2 , Richard Walshaw 2

1 University of Liverpool, School of Health Sciences, Liverpool, United Kingdom. 2 Clatterbridge Cancer Centre NHS Foundation Trust, Radiotherapy, Liverpool, United Kingdom. 3 Countess of Chester NHS Foundation Trust, Radiology, Chester, United Kingdom

Purpose/Objective:

High-dose-rate (HDR)-brachytherapy is widely adopted as an effective treatment for prostate cancer 1 , delivered as a monotherapy, a boost in combination with external beam radiotherapy (EBRT), or a salvage approach. HDR brachytherapy provides highly conformal radiation delivery, resulting in reduced toxicity rates compared to EBRT 1,2 . Patients eligible for HDR-brachytherapy generally have a good prognosis; as a result, it is essential to consider long term effects that can present from 6-months to decades post-treatment. Although previous studies did not demonstrate significant rates of late toxicity 1-3 , limited data are available using patient-reported outcome measures (PROMs) to assess long-term urinary, bowel and sexual toxicities following HDR-brachytherapy. PROMs are not widely used within UK radiotherapy departments outside of clinical trials 4 , yet research indicates PROMs provide a more robust assessment of toxicity incidence/severity compared with clinician-reported outcomes 5,6 . Healthcare professionals adequately skilled to conduct PROMs follow-up may include Radiation Therapists (RTTs). Studies demonstrate positive findings using RTT-led approaches to identify EBRT toxicities in prostate cancer follow up 7-11 . With the RTT role continuously advancing, there is opportunity to further explore roles in HDR-brachytherapy long-term follow-up. This clinical audit aimed to conduct RTT-led long-term patient follow-up post-HDR brachytherapy, utilising PROMs to identify the incidence/severity of late toxicities. This included evaluation of lifestyle factors during treatment and at present to assess any association with long-term toxicity.

Material/Methods: